R
Riccardo Centurioni
Researcher at Unica Corporation
Publications - 51
Citations - 1153
Riccardo Centurioni is an academic researcher from Unica Corporation. The author has contributed to research in topics: Thalidomide & Thrombotic thrombocytopenic purpura. The author has an hindex of 17, co-authored 51 publications receiving 1016 citations. Previous affiliations of Riccardo Centurioni include Marche Polytechnic University.
Papers
More filters
Journal ArticleDOI
Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP
E Bobbio-Pallavicini,Luigi Gugliotta,Riccardo Centurioni,Camillo Porta,Nicola Vianelli,Atto Billio,F Tacconi,Edoardo Ascari +7 more
TL;DR: The results suggest the usefulness of antiplatelet agents in the treatment of acute phase TTP patients and one-year ticlopidine maintenance therapy appears to be beneficial in preventing TTP relapses; however, only the completion of an adequate follow-up for all patients will definitively confirm this observation.
Journal ArticleDOI
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma
Massimo Offidani,Laura Corvatta,Maria Novella Piersantelli,Giuseppe Visani,Francesco Alesiani,Marino Brunori,Piero Galieni,Massimo Catarini,Maurizio Burattini,Riccardo Centurioni,Mario Ferranti,Serena Rupoli,Anna Rita Scortechini,Luciano Giuliodori,Marco Candela,Debora Capelli,M Montanari,Attilio Olivieri,Antonella Poloni,Claudia Polloni,Monica Marconi,Pietro Leoni +21 more
TL;DR: ThaDD is a very effective regimen with manageable toxicity in the treatment of elderly patients with newly diagnosed multiple myeloma and time to progression, event-free survival, and overall survival projected at 3 years were significantly higher in those patients achieving a response of at least VGPR versus those who did not.
Journal ArticleDOI
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study
Massimo Offidani,Laura Corvatta,Monica Marconi,Giuseppe Visani,Francesco Alesiani,Marino Brunori,Piero Galieni,Massimo Catarini,Maurizio Burattini,Riccardo Centurioni,Serena Rupoli,Anna Rita Scortechini,Luciano Giuliodori,Marco Candela,Debora Capelli,M Montanari,Attilio Olivieri,Maria Novella Piersantelli,Pietro Leoni +18 more
TL;DR: The combination of pegylated liposomal doxorubicin, dexamethasone an thalidomide is safe and very effective in advanced multiple myeloma.
Journal ArticleDOI
Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: A single center experience
Attilio Olivieri,Massimo Offidani,M Montanari,Luca Ciniero,Cantori I,Laura Ombrosi,Cristiana M. Masia,Riccardo Centurioni,Stefania Mancini,Marino Brunori,Pietro Leoni +10 more
TL;DR: When G-CSF is employed both for PBPC mobilization and after PBPC transplantation, the CD34+ cell number is the only factor that affects hemopoietic recovery and the optimal peripheral blood progenitor cell number for rapid engraftment is found.
Journal ArticleDOI
Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF.
Massimo Offidani,L Corvatta,Attilio Olivieri,Serena Rupoli,J Frayfer,Anna Mele,E. Manso,M Montanari,Riccardo Centurioni,P. Leoni +9 more
TL;DR: Although Gram-positive organisms were the major cause of bacteremia, a glycopeptide in the empirical antibiotic regimen did not affect infection outcome and in PBPCT recipients, early and late opportunistic infections were notably absent, which was at variance with what was seen with bone marrow recipients.